Showing results (1481-1490 of 1,502) with videos related to
Sort By:
Pageof 151
MMWR. Morbidity and Mortality Weekly Report|July 29, 2016
Update: Interim Guidance for Health Care Providers Caring for Pregnant Women with Possible Zika Virus Exposure - United States, July 2016Titilope Oduyebo, Irogue Igbinosa, Emily E Petersen, et al.Frontiers in Neurology|April 2, 2021
The Delayed Neuropathological Consequences of Traumatic Brain Injury in a Community-Based SampleNadia Postupna, Shannon E Rose, Laura E Gibbons, et al.Journal of Medicinal Chemistry|July 22, 2016
Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 InhibitorsErin F DiMauro, Stephen Altmann, Loren M Berry, et al.The New England Journal of Medicine|July 13, 2012
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in BotswanaMichael C Thigpen, Poloko M Kebaabetswe, Lynn A Paxton, et al.Biorxiv : the Preprint Server for Biology|July 15, 2025
An Anaerobic Pathogen Rewires Host Metabolism to Fuel Oxidative Growth in the Inflamed GutLuisella Spiga, Ryan T Fansler, Alexandra Grote, et al.Cell|May 1, 2026
An anaerobic pathogen rewires host metabolism to fuel oxidative growth in the inflamed gutLuisella Spiga, Ryan T Fansler, Yifan Wu, et al.Journal of Medicinal Chemistry|March 14, 2017
Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic LiabilitiesMatthew M Weiss, Thomas A Dineen, Isaac E Marx, et al.MMWR. Morbidity and Mortality Weekly Report|August 28, 2020
COVID-19 Among American Indian and Alaska Native Persons - 23 States, January 31-July 3, 2020Sarah M Hatcher, Christine Agnew-Brune, Mark Anderson, et al.Journal of Medicinal Chemistry|August 6, 2010
Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitorVictor J Cee, Laurie B Schenkel, Brian L Hodous, et al.Bioorganic & Medicinal Chemistry Letters|March 19, 2011
Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitorsJohn L Buchanan, John R Newcomb, David P Carney, et al.Pageof 151